IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 23, Issue 7 Ser. 3 (July. 2024), PP 32-35
www.iosrjournals.org

Quinolones in Pediatric Practice: Balancing Efficacy and Safety

Dr. Ashish Goel* [(1),] Dr. Paula Goel [(2)]
Department of Pediatrics, Fayth Clinic Mumbai, India
**Corresponding Author: ashishgoel@outlook.com*

Abstract
Quinolones, a class of broad-spectrum antibiotics, have significantly impacted the treatment of bacterial infections since their discovery in the 1960s. Despite their efficacy in adults, the use of quinolones in pediatric practice remains contentious due to potential side effects and the emergence of resistance. This review explores the historical context, classification, mechanisms of action, and resistance patterns associated with quinolones, particularly focusing on their use in children. Key case studies highlight clinical scenarios where quinolones are employed, emphasizing the need for safer alternatives. Adverse effects, such as CNS disturbances, renal issues, and musculoskeletal complaints, are discussed, emphasizing the necessity for cautious application in pediatric settings. Recent research trends and emerging alternatives, including bacteriophage therapy and next-generation sequencing, are examined for their potential to mitigate resistance. Global health implications are considered, noting regional variations in quinolone use and regulatory approaches. Ethical considerations stress the importance of balancing immediate treatment needs with long-term resistance risks. Ultimately, this review advocates for prudent quinolone use, reserved for severe infections with multidrug-resistant pathogens, and calls for enhanced antibiotic stewardship to safeguard pediatric health.

Keywords: *Quinolones, Ciprofloxacin, Levofloxacin, Moxifloxacin, Antibiotic resistance, Public Health*

Date of Submission: 01-07-2024 Date of Acceptance: 11-07-2024

I. Introduction

Quinolones, a class of broad-spectrum antibiotics, have played a significant role in treating various bacterial infections since their accidental discovery in the 1960s. The first quinolone, nalidixic acid, was initially found during the synthesis of chloroquine, a medication used to treat malaria (Molecules, 2021). This discovery paved the way for the development of more potent derivatives such as ciprofloxacin, levofloxacin, and moxifloxacin, which have since become critical in combating bacterial infections due to their broad antibacterial spectrum, high oral bioavailability, and excellent tissue penetration (MDPI, 2021).

Initially, quinolones were celebrated for their effectiveness in treating a wide range of infections in adults. However, the introduction of quinolones in pediatric practice has been met with caution due to concerns about potential side effects and the emergence of antibiotic resistance (Patel & Poretz, 2001; Mandell et al., 2010). The early toxicology studies on quinolones highlighted the risk of cartilage injury in weight-bearing joints of juvenile animals, which raised alarms about their safety in children. These findings led to extensive studies and clinical trials to evaluate the safety and efficacy of quinolones in pediatric patients (American Academy of Pediatrics, 2018). Despite initial concerns, certain quinolones like ciprofloxacin and levofloxacin were approved for pediatric use in specific situations, such as inhalational anthrax, plague, complicated urinary tract infections (UTIs), and pyelonephritis (AAP, 2023).

However, the widespread use of quinolones has led to a significant rise in antimicrobial resistance, making it essential to use these drugs judiciously. Resistance to quinolones can develop through multiple mechanisms, including mutations in target enzymes, plasmid-mediated resistance, and changes in bacterial cell permeability. The global health implications of quinolone resistance are profound, necessitating international collaboration and stringent antibiotic stewardship to manage and mitigate this growing threat (WHO, 2018). Clinical practice in the United States and India shows that nearly 20% of pediatric prescriptions include quinolones, primarily for severe infections when no safer alternatives are available (Mandell et al., 2010). While quinolones remain a valuable tool in the fight against bacterial infections, their use in pediatric practice must be carefully managed to maximize benefits and minimize risks. Continued research and the development of new antibiotics and alternative therapies are essential to ensure effective and safe treatment options for children (MDPI, 2021).

Classification and Spectrum of Activity

Quinolones are categorized based on their spectrum of activity:

- **Ciprofloxacin**: Approved for children aged 1 to 17 years in 2004, it boasts strong anti-pseudomonal activity (Bhutta & Mintz, 2010). It is effective against a wide range of gram-negative bacteria, including *Escherichia coli, Klebsiella pneumoniae, and Enterobacter species*, as well as some gram-positive bacteria.
- **Levofloxacin**: The only respiratory quinolone found to be safe in children, effective against *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Mycobacterium tuberculosis* (World Health Organization, 2018). It also has activity against other gram-positive and gram-negative organisms.
- **Moxifloxacin**: Exhibits high anti-tubercular activity and is another respiratory quinolone (Parry et al., 2002). It is effective against a broad spectrum of pathogens, including gram-positive bacteria like *Streptococcus pneumoniae* and gram-negative bacteria such as *Haemophilus influenzae*. It also has activity against anaerobes and atypical pathogens like *Mycoplasma pneumoniae*.
- **Ofloxacin**: This fluoroquinolone is effective against a variety of gram-negative bacteria, including *Pseudomonas aeruginosa*, as well as some gram-positive bacteria. It is used for treating urinary tract infections, respiratory infections, and skin infections.
- **Norfloxacin**: Primarily used for treating urinary tract infections, norfloxacin is effective against gram-negative bacteria such as *Escherichia coli, Proteus mirabilis,* and *Klebsiella pneumoniae*. It has limited activity against gram-positive bacteria.
- **Delafloxacin**: A newer fluoroquinolone with enhanced activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), as well as gram-negative pathogens. It is used for treating acute bacterial skin and skin structure infections.
- **Gatifloxacin**: Effective against a broad range of gram-positive and gram-negative bacteria, including *Streptococcus pneumoniae, Haemophilus influenzae*, and *Moraxella catarrhalis*. It is used for respiratory tract infections and ocular infections.

All quinolones demonstrate excellent activity against aerobic gram-negative bacteria, making them invaluable in treating infections caused by these pathogens (Mandell et al., 2003). Quinolones target bacterial topoisomerases, primarily DNA gyrase and topoisomerase IV, enzymes crucial for DNA replication and transcription. By converting these enzymes into toxic agents, quinolones induce double-stranded breaks in bacterial DNA, leading to cell death. This mechanism underpins their broad-spectrum bactericidal action (Mandell et al., 2003; American Academy of Pediatrics, 2018).

Clinical Indications and Case Studies

Quinolones offer excellent oral bioavailability but are restricted in outpatient settings due to potential side effects. They are indicated in children with multi-drug resistant (MDR) pathogens when no safer alternatives are available, especially when parenteral therapy is unfeasible (Kliegman et al., 2015).

Case Study 1: Enteric Fever in a 10-Year-Old Girl

A 10-year-old girl presented to the emergency department with a five-day history of high fever, poor food intake, general malaise, and significant fatigue. Physical examination revealed tachycardia and splenomegaly, raising clinical suspicion of enteric fever. Initial laboratory tests, including complete blood count and liver function tests, were indicative of an ongoing infection, prompting the attending physician to initiate empirical antibiotic therapy with oral ciprofloxacin.

Despite the treatment, the girl's fever persisted, and her condition showed little improvement. Blood cultures taken on admission later confirmed the presence of *Salmonella enterica* serotype Typhi, resistant to nalidixic acid, which suggested a potential higher failure rate for ciprofloxacin. Given the resistance profile, the medical team decided to switch her treatment to azithromycin, a safer and more effective alternative for nalidixic acid-resistant *Salmonella* strains. After the change in antibiotics, the patient's symptoms gradually improved, and she was discharged with a plan for follow-up to ensure complete recovery.

Case Study 2: Nosocomial Infection in an 8-Year-Old Boy

An eight-year-old boy, admitted to the Pediatric Intensive Care Unit (PICU) for polytrauma following a severe road traffic accident, developed a high-grade fever on the eighth day of hospitalization. Initial management of his injuries included multiple surgical interventions and broad-spectrum antibiotics to prevent infection. However, despite these measures, the child exhibited signs of sepsis, prompting further investigation.

Urine cultures and blood tests were conducted, revealing the presence of *Klebsiella pneumoniae*, a common nosocomial pathogen. Given the organism's multidrug-resistant profile, the medical team considered the use of quinolones, specifically ciprofloxacin, due to its effectiveness against *Pseudomonas aeruginosa* and other gram-negative organisms.

Ciprofloxacin was administered intravenously, and the patient was closely monitored for any adverse reactions. Over the next few days, the boy's fever subsided, and his clinical condition improved significantly. He continued to receive ciprofloxacin for a total of 14 days to ensure the eradication of the infection. Follow-up cultures showed no growth of the pathogen, and the patient was eventually discharged in stable condition.

These two cases highlight the critical role of quinolones in treating severe nosocomial infections in pediatric patients, particularly when dealing with multidrug-resistant organisms. It highlights the need for continuous monitoring of resistance patterns, the importance of having alternative antibiotics available for effective treatment and the importance of using these antibiotics judiciously to manage such infections effectively while minimizing the risk of resistance and adverse effects.

II. Discussion

The use of quinolones in pediatric practice has sparked considerable debate due to their efficacy and the associated risks of adverse effects and resistance. Common adverse effects of quinolones include CNS disturbances such as headaches, dizziness, sleep disturbances, mood changes, confusion, psychosis, tremors, and seizures (Tamma & Newland, 2018; Molecules, 2021). Renal issues, including azotemia, chills, angioedema, and anaphylaxis, have also been noted (Bhutta, 2006). Musculoskeletal effects like arthralgia and arthropathy are particularly concerning in cystic fibrosis patients on prolonged therapy (Gupta & Datta, 2011). While studies have not demonstrated negative impacts on linear growth in children, the potential for severe side effects necessitates cautious use of quinolones (Centers for Disease Control and Prevention, 2020; Molecules, 2023).

The rise in quinolone resistance is alarming and can be attributed to several mechanisms. Target-mediated resistance involves mutations in quinolone target enzymes that reduce drug binding (Chopra & Roberts, 2001). Plasmid-mediated resistance alters drug metabolism or increases efflux, thereby reducing intracellular drug concentrations (Threlfall & Ward, 2001). Additionally, chromosome-mediated resistance involves decreased porin expression or increased efflux pump expression, hindering drug entry and promoting removal from bacterial cells (Heymann, 2015).

Recent studies underscore the importance of monitoring resistance patterns closely. For example, Tamma and Newland (2018) highlight the rising fluoroquinolone resistance in pediatric populations, necessitating new guidelines for their use. Additionally, newer molecular diagnostic tools, such as multiplex polymerase chain reaction (mPCR) assays, are promising for reducing unnecessary antibiotic use by providing quicker and more accurate diagnoses of infections (Academic OUP, 2023).

New antibiotics and alternative therapies are being explored to address quinolone limitations. Research into bacteriophage therapy offers potential as a targeted approach to treating bacterial infections with a reduced risk of resistance development (Redgrave et al., 2014). Advances in next-generation sequencing and molecular testing are also improving the precision of antibiotic treatments (Molecules, 2023).

Historically, quinolones have been widely used due to their broad-spectrum activity and efficacy against various bacterial infections. In the United States, quinolones like ciprofloxacin and levofloxacin are commonly prescribed, but their use in children is often limited to cases where no safer alternatives are available (Tamma & Newland, 2018). In contrast, in countries like India, the use of quinolones in pediatric populations is more prevalent due to higher rates of antibiotic resistance and limited access to alternative treatments (Mandell et al., 2010). In Europe, the use of quinolones in children is highly regulated, with strict guidelines to minimize the risk of adverse effects and resistance. The European Medicines Agency has conducted several reviews and issued warnings regarding the potential risks associated with quinolone use, leading to more cautious prescribing practices (BNF via NICE, 2021).

In regions with high rates of antibiotic resistance, judicious use of these drugs is crucial to preventing the spread of multidrug-resistant (MDR) pathogens. International collaboration and data sharing are essential for developing effective strategies to combat resistance (Levine & Simon, 2013). The World Health Organization emphasizes the need for global efforts to monitor and manage antibiotic resistance (World Health Organization, 2018).

Ethical considerations surrounding quinolone use in children involve balancing the immediate need to treat severe infections with the long-term consequences of antibiotic resistance. Physicians must weigh the potential benefits against the risks, considering each patient's unique circumstances. This also includes considering the broader impact on community health and the environment, as excessive use of antibiotics in both human and veterinary medicine contributes to resistance (Crum-Cianflone, 2008; Molecules, 2021).

In developing countries, quinolones remain an essential part of the antibiotic arsenal due to their affordability and effectiveness. However, this widespread use has also contributed to the rapid emergence of resistant bacterial strains, making it crucial for global health initiatives to focus on antibiotic stewardship and the development of new treatments.

III. Conclusion

Quinolones should be used sparingly in pediatric practice, reserved for cases involving MDR organisms where no safer alternatives exist. The growing concern of drug resistance and potential adverse reactions highlights the need for careful antibiotic stewardship. Safer alternatives should always be considered first to ensure the best outcomes for pediatric patients.

Consent and Privacy

The parents of both patients provided Informed Consent for publication.

Contributors

Paula Goel attended both patients. Ashish Goel and Paula Goel conceptualized this idea and drafted the manuscript.

Conflict of Interest

The authors have no conflicts of interest to declare.

Funding

No funding was received for this article.

REFERENCES

[1]. Patel, S. J., & Poretz, D. M. (2001). The role of quinolones in pediatric infections. Pediatric Infectious Disease Journal, 20(10), 973-974.
[2]. Mandell, G. L., Bennett, J. E., & Dolin, R. (2010). Principles and Practice of Infectious Diseases (7th ed.). Churchill Livingstone.
[3]. Bhutta, Z. A., & Mintz, E. D. (2010). Enteric fever in children: The implications of acquired resistance to ciprofloxacin. Pediatric Infectious Disease Journal, 29(3), 223-225.
[4]. World Health Organization. (2018). Typhoid vaccines: WHO position paper – March 2018. Weekly Epidemiological Record, 93(13), 153-172.
[5]. Parry, C. M., Hien, T. T., Dougan, G., White, N. J., & Farrar, J. J. (2002). Typhoid fever. New England Journal of Medicine, 347(22), 1770-1782.
[6]. Mandell, L. A., & File, T. M. (2003). Acute bacterial rhinosinusitis in adults: Management guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 37(4), 372-376.
[7]. American Academy of Pediatrics. (2018). Red Book: 2018 Report of the Committee on Infectious Diseases (31st ed.). American Academy of Pediatrics.
[8]. Chopra, I., & Roberts, M. (2001). Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiology and Molecular Biology Reviews, 65(2), 232-260.
[9]. Threlfall, E. J., & Ward, L. R. (2001). Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerging Infectious Diseases, 7(3), 448-450.
[10]. Heymann, D. L. (2015). Control of Communicable Diseases Manual (20th ed.). American Public Health Association.
[11]. Kliegman, R. M., Stanton, B. F., St. Geme, J. W., Schor, N. F., & Behrman, R. E. (2015). Nelson Textbook of Pediatrics (20th ed.). Elsevier.
[12]. Murray, P. R., Rosenthal, K. S., & Pfaller, M. A. (2015). Medical Microbiology (8th ed.). Elsevier.
[13]. Tamma, P. D., & Newland, J. G. (2018). The use of fluoroquinolones in children. Pediatrics, 142(4), e20181079.
[14]. Bhutta, Z. A. (2006). Current concepts in the diagnosis and treatment of typhoid fever. BMJ, 333(7558), 78-82.
[15]. Gupta, V., & Datta, P. (2011). Next-generation sequencing for comparative analysis of two Salmonella enterica serotype Typhi isolates: Sensitive and resistant to ciprofloxacin. Journal of Clinical Microbiology, 49(11), 4394-4397.
[16]. Centers for Disease Control and Prevention. (2020). Antibiotic resistance threats in the United States. Retrieved from CDC Website.
[17]. Levine, M. M., & Simon, R. (2013). The gathering storm: Is untreatable typhoid fever on the way? MBio, 4(6), e00482-13.
[18]. Redgrave, L. S., Sutton, S. B., Webber, M. A., & Piddock, L. J. V. (2014). Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends in Microbiology, 22(8), 438-445.
[19]. Crum-Cianflone, N. F. (2008). Quinolones: A comprehensive review. Clinical Medicine: Therapeutics, 1, 465-494.
[20]. Roy, S., Viswanathan, R., & Singh, R. (2015). Antibiotic resistance in pediatric septicemia in India. Journal of Infection and Chemotherapy, 21(8), 561-563.
[21]. Molecules. (2021). Safety of Quinolones in Children: A Systematic Review and Meta-Analysis. Pediatric Drugs.
[22]. Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020). Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules, 25(23), 5662.
[23]. BNF via NICE. (2021). Treatment summaries for quinolones. British National Formulary. Retrieved from NICE Website.
[24]. Academic OUP. (2023). PIDS/IDSA Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics. Clinical Infectious Diseases. Retrieved from OUP Website.
[25]. Molecules. (2023). Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents. Molecules. Retrieved from MDPI Website.